Ziftomenib is a Small Molecule owned by Kura Oncology, and is involved in 1 clinical trial, which is ongoing.

Ziftomenib (KO-539) acts by inhibiting menin-MLL1 interaction. Mixed-lineage leukemia (MLL) complex acts as a co-activator of androgen receptor (AR) signaling. AR directly interacts with the MLL complex via menin MLL subunit. Menin is over expressed in malignancies promoting tumor growth and correlates with poor overall survival. The drug candidate by inhibiting menin-MLL interaction, blocks AR signaling and inhibits the growth of tumors.

The revenue for Ziftomenib is expected to reach a total of $1.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Ziftomenib NPV Report.

Ziftomenib was originated by University of Michigan and is currently owned by Kura Oncology.

Ziftomenib Overview

Ziftomenib (KO-539) is under development for the treatment of MLL- rearranged leukemias including NPM1 mutant or DNMT3A mutant refractory/relapsed acute myelocytic leukemia. The drug candidate is administered orally as a capsule. It targets menin-MLL protein interaction.

Kura Oncology Overview

Kura Oncology is a biopharmaceutical company that discovers and develops therapeutics for the treatment of solid tumors and blood cancers. The company’s lead drug candidate Tipifarnib, an inhibitor of farnesyl transferase, an oral investigational drug candidate intended for the treatment of various types of cancer including HRAS mutant head and neck cancer, peripheral T-cell lymphomas, myelodysplastic syndromes and chronic myelomonocytic leukemia. Its other candidates include KO-947, an investigational drug candidate for mitogen-activated protein kinase pathway tumors and KO-539, a small molecule inhibitor for the treatment of acute leukemia. Kura Oncology is headquartered in San Diego, California, the US.

The operating loss of the company was US$131.5 million in FY2021, compared to an operating loss of US$91.9 million in FY2020. The net loss of the company was US$130.5 million in FY2021, compared to a net loss of US$89.6 million in FY2020.

Quick View – Ziftomenib

Report Segments
  • Innovator
Drug Name
  • Ziftomenib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.